A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX7486 as a Single Agent and in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 28 Jul 2017
At a glance
- Drugs PLX 7486 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Plexxikon
- 14 Sep 2016 Planned number of patients changed from 160 to 90.
- 09 Oct 2015 Trial focus has been changed from adverse reactions(AR) to pharmacokinetics and adverse reactions(PK+AR), as endpoints has been added as reported by ClinicalTrials.gov record.
- 09 Oct 2015 Planned number of patients changed from 118 to 160 as reported by ClinicalTrials.gov record.